Hepatitis C treatment difficult in older patients
Posted on: Wednesday, 18 January 2006, 14:25 CST
NEW YORK (Reuters Health) - Because of side effects, patients over the age of 60 with hepatitis C find it more difficult to stick with standard treatments than do their younger counterparts, according to a study in Japan.
Impaired heart, lung and kidney function can make older patients more susceptible to anemia induced by ribavirin, one of the drugs used for treating hepatitis C, explain Dr. Yoshiaki Iwasaki, from Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, and colleagues.
Iwasaki's group analyzed outcomes among 208 patients with chronic hepatitis C. The treatment involved injections of interferon daily for 2 weeks then three times weekly for 22 weeks, and daily ribavirin.
The researchers report in the medical journal Hepatology that only 92 (44 percent) continued without dose reductions until the end of treatment.
Rates of discontinuation or dose reduction were 38 percent in those younger than 50 years old, 48 percent in those between 50 and 59, and 77 percent in patients 60 or older.
Overall, the treatment was successful in eliminating the hepatitis C virus in 37 percent of the patients, with age being associated with a poorer response rate.
"Treatment schedule should be modified, or other therapeutic modalities should be considered for older patients with chronic hepatitis C," Iwasaki's group concludes.
SOURCE: Hepatology, January 2006.
Source: REUTERS
Related Articles
- Twice Daily Oral Medication Shows Promise in Treating Patients with Hepatitis C
- Extending Treatment After Liver Transplant May Benefit Patients With Hepatitis C Recurrence
- Study Points to New Era in Hepatitis C Treatment
- Ground-Breaking Combination of All-Oral Agents Demonstrates Potential as Hepatitis C Treatment Regimen
- PEGASYS(R) Proven Effective as Hepatitis C Treatment for Latino Patients, According to Article in The New England Journal of Medicine
- Only 44.4 Percent of Parkinson's Disease Patients Receive Drug Treatment Within One Year of Being Diagnosed
- Review Examines the Use of Sirtex's SIR-Spheres(R) Microspheres in Patients With Hepatic Colorectal Cancer Metastases
- China Releases Guidelines on Hepatitis B Treatment
- Patients with Hepatitis C using more healthcare resources
- FDA Approves Pegasys and Copegus As Only Hepatitis C Treatment for HIV Patients
User Comments (0)

RSS Feeds